Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

Share Price is delayed by 15 minutes
Get Live Data
700.00    -10.00 (-1.41%)
Bid:
700.00
Ask:
706.00
Spread: 6.00 (0.857%)
Market Cap: £346.93m
ELIX Live PriceLast checked at - London Stock Exchange

Intraday Elixirr International Share Chart

Board Changes

10 Dec 2024 07:00

RNS Number : 4806P
Elixirr International PLC
10 December 2024
 

 

ELIXIRR INTERNATIONAL PLC

("Elixirr", the "Company" or "Group")

Board Changes

Elixirr International plc (AIM:ELIX), an established, global, award-winning, challenger consultancy, announces the following changes to its Board of Directors.

Graham Busby, Co-Founder & Chief Financial Officer, will be appointed as Deputy Chief Executive Officer of Elixirr with effect from 1 January 2025. In this role, Graham will continue to be responsible for the Group's acquisition strategy which he has led since 2020. Nick Willott, Finance Director and Company Secretary, will be appointed as Chief Financial Officer with effect from 1 January 2025 and is expected to join the Board of Elixirr following completion of requisite due diligence procedures. Stephen Newton will continue as Chief Executive Officer.

The Company also announces that Ian Ferguson, Co-Founder & Director, will step down from the Board on 1 January 2025, becoming a Board Advisor.

A further announcement will be made in due course regarding Nick's formal appointment to the board, containing requisite disclosures in accordance with Schedule Two, paragraph (g) of the AIM Rules for Companies.

Commenting on the board changes, Founder & CEO of Elixirr, Stephen Newton said:

"We are delighted to announce the appointments of Graham and Nick as Deputy CEO and CFO respectively. Their deep understanding of the business, together with their technical knowledge and market expertise will further strengthen the Board and support the Company as it continues its strong trajectory of growth. Graham has operated as de facto Deputy Chief Executive Officer for several years working side-by-side with me every day, and Nick has performed exceptionally as our Finance Director and Company Secretary since joining us in 2020. We will continue to work together as a team in the years going forward as we continue to disrupt the consulting market.

The Board, and I personally, wish to thank Ian for his significant contributions as a Board Director and we look forward to his continued counsel as an ongoing advisor to the Board as well as receive his guidance and wisdom on special projects, particularly around M&A."

Enquiries: 

For enquiries, please refer to our Investor Contacts page:

https://www.elixirr.com/investors/investor-contacts

Elixirr International plc +44 (0)20 7220 5410  

Stephen Newton, Chief Executive Officer

Graham Busby, Chief Financial Officer

investor-relations@elixirr.com

Cavendish Capital Markets Ltd (Nominated Adviser & Broker) +44 (0)20 7220 0500

Stephen Keys, Callum Davidson (Corporate Finance),

Sunila De Silva (ECM)

 

About Elixirr International plc

Elixirr is an award-winning global consulting firm working with clients across a diverse range of industries, markets and geographies.

Founded in 2009, the firm set out to be the 'challenger consultancy' and do things differently than the large corporate consultancies dominating the industry: working openly and collaboratively with clients from start to finish, delivering outcomes based on innovative thinking, not methodology, and treating each client's business like their own. Elixirr has been quoted on the AIM market of the London Stock Exchange since 2020. In addition to strong organic growth, Elixirr has acquired seven boutique firms - Den Creative, Coast Digital, The Retearn Group, iOLAP, Responsum, Insigniam and Hypothesis - to grow the Group's capabilities, diversify the business, expand into new geographies and access new clients.

 

 This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAURUNRSOUUARA
Date   Source Headline
25th Oct 202412:01 pmRNSDirector/PDMR Shareholding
25th Oct 20247:00 amRNSResult of Secondary Placing
24th Oct 20244:35 pmRNSProposed Secondary Placing
21st Oct 20247:00 amRNSAcquisition of Hypothesis Group, LLC
14th Oct 20247:00 amRNSRevolving Credit Facility
1st Oct 20247:00 amRNSInvestor Presentation
23rd Sep 20247:00 amRNSInterim Results
31st Jul 20245:00 pmRNSDirector/PDMR Shareholding
25th Jul 20247:00 amRNSPDMR/PCA Dealings
12th Jul 20244:15 pmRNSDirector/PDMR Shareholding
9th Jul 202411:45 amRNSPurchase of Shares by Employee Benefit Trust
3rd Jul 202410:30 amRNSDirector Dealing
25th Jun 20249:55 amRNSResult of AGM
31st May 20247:00 amRNSPosting of Annual Report and Accounts
21st May 20246:20 pmRNSDirector Declaration
24th Apr 20247:00 amRNSGrant of Share Options
22nd Apr 20247:00 amRNSFinal Results
8th Apr 20247:00 amRNSNotice of FY 23 Results and Investor Presentation
26th Jan 20247:00 amRNSDirector Dealing
8th Jan 20247:00 amRNSTrading Update and Change to Dividend Policy
11th Dec 20237:00 amRNSAcquisition of Insigniam LLC and Insigniam SAS
18th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSAcquisition of Responsum, Inc.
13th Jun 202310:45 amRNSResult of AGM
24th May 20231:31 pmRNSHolding(s) in Company
19th May 20237:00 amRNSPosting of Annual Report and Accounts
10th May 20233:00 pmRNSDirector/PCA Dealings
26th Apr 20237:00 amRNSGrant of Share Options
12th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
4th Apr 20233:00 pmRNSDirector Dealing
3rd Apr 20239:15 amRNSDirector Dealing
3rd Apr 20237:00 amRNSFinal Results
28th Mar 20237:00 amRNSInvestor Presentation
27th Feb 20239:05 amRNSSecond Price Monitoring Extn
27th Feb 20239:00 amRNSPrice Monitoring Extension
27th Feb 20237:00 amRNSTrading Update
24th Feb 20232:05 pmRNSSecond Price Monitoring Extn
24th Feb 20232:00 pmRNSPrice Monitoring Extension
24th Feb 202311:05 amRNSSecond Price Monitoring Extn
24th Feb 202311:00 amRNSPrice Monitoring Extension
29th Nov 20221:15 pmRNSInvestor Presentation
11th Nov 20227:00 amRNSDirector Dealing
20th Oct 20227:00 amRNSPCA Dealing
6th Oct 20227:00 amRNSPurchase of Shares by Employee Benefit Trust
20th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
29th Jul 20224:41 pmRNSSecond Price Monitoring Extn
29th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20221:45 pmRNSPDMR/PCA Dealing
7th Jul 202211:15 amRNSPCA Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.